Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celcuity Inc CELC

Healthcare Biotechnology
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes... see more

Recent & Breaking News (NDAQ:CELC)

Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call

GlobeNewswire August 3, 2023

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

GlobeNewswire July 31, 2023

Celcuity Set to Join Russell 2000 and 3000 Indexes

Accesswire June 20, 2023

Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences

Accesswire May 24, 2023

Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Accesswire May 15, 2023

Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress

Accesswire May 12, 2023

Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call

Accesswire May 8, 2023

Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress

Accesswire May 8, 2023

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

Accesswire April 18, 2023

Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference

Accesswire April 12, 2023

Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Accesswire March 23, 2023

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call

Accesswire March 16, 2023

Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

Accesswire March 15, 2023

Celcuity to Participate in Cowen's 43rd Annual Health Care Conference

Accesswire March 1, 2023

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium

Accesswire February 16, 2023

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Celcuity Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

PR Newswire December 20, 2022

Celcuity Closes $100 Million Private Placement

Accesswire December 12, 2022

Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium

Accesswire December 9, 2022

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer

Accesswire December 7, 2022

Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium

Accesswire November 22, 2022